Rifaximin: all 149 studies that test it
Page 2 of 2. Open to participants first (24), then studies with results posted, then the rest; newest registration first within each.
- GutHeart: Targeting Gut Microbiota to Treat Heart FailureStatus unknownNCT02637167Phase 2
- Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn DiseaseTerminatedNCT02620007Phase 2
- Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver ResectionTerminatedNCT02555293Phase 2
- Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal VaricesStatus unknownNCT02508623Phase 3
- Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TDCompletedNCT02498301Not applicable
- Rifaximin Use in Severe Alcoholic HepatitisStatus unknownNCT02485106Phase 3
- Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal BacterialTerminatedNCT02439307Not applicable
- Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial VaginosisTerminatedNCT02376972Phase 2
- Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.CompletedNCT02321371Not applicable
- To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related ParkinsonismCompletedNCT02265484Not applicable
- Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled TrialStatus unknownNCT02190357Phase 4
- Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal BleedingCompletedNCT02158182Phase 4
- Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial PeritonitisStatus unknownNCT02120196Phase 3
- Effects of Rifaximin in Patients With Acute Alcoholic HepatitisStatus unknownNCT02116556Phase 2
- A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal FailureWithdrawnNCT02086825Phase 3
- Rifaximin Predicts the Complications of Decompensated CirrhosisStatus unknownNCT02074280Phase 4
- Immunohistology in USDD and Correlation Between Bacterial Flora and PhlogosisCompletedNCT02068482Phase 4
- Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPSCompletedNCT02016196Phase 3
- Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic PatientsWithdrawnNCT02011841Phase 3
- The Effects of Rifaximin Therapy in Irritable Bowel SyndromeCompletedNCT02009618Not applicable
- Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis PatientsCompletedNCT02009592Not applicable
- Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In CirrhosisTerminatedNCT01951209Not applicable
- The Rifaximin Study in CVIDCompletedNCT01946906Phase 4
- Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver CirrhosisCompletedNCT01904409Phase 2
- Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic PatientsStatus unknownNCT01897051Phase 2/3
- Quality of Life and Nutritional Improvements in Cirrhotic PatientsTerminatedNCT01842113Phase 4
- Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time MeasurementCompletedNCT01773538Not applicable
- Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With CirrhosisCompletedNCT01769040Phase 4
- A Pilot Study of Xifaxan to Treat Patients With PSCCompletedNCT01695174Phase 1
- Rifaximin for Preventing Relapse of Clostridium Associated DiarrhoeaCompletedNCT01670149Phase 4
- Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver DiseaseWithdrawnNCT01654939Phase 4
- Rifaximin for Functional DyspepsiaCompletedNCT01643083Phase 2/3
- Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver TransplantStatus unknownNCT01603108Phase 2
- Rifaximin Treatment of Papulopustular RosaceaWithdrawnNCT01359228Phase 2
- Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized TrialCompletedNCT01218568Not applicable
- Study of Rifaximin in Minimal Hepatic EncephalopathyCompletedNCT01069133Phase 1/2
- Prophylactic Treatment of Travellers' Diarrhoea With RifaximinCompletedNCT00979056Phase 3
- Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)CompletedNCT00967096Phase 1
- Does Small Intestinal Bacterial Overgrowth Contribute to Functional DyspepsiaCompletedNCT00956397Not applicable
- Single Daily Dose Rifaximin for the Treatment of Travelers' DiarrheaWithdrawnNCT00875875Phase 4
- Rifaximin Versus Lactulose in Renal FailureWithdrawnNCT00748904Phase 4
- Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy VolunteersCompletedNCT00743912Phase 1
- Induction of Clinical Response Using Rifaximin in Crohn's DiseaseCompletedNCT00603616Phase 2
- Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.CompletedNCT00328380Phase 3
- Rifaximin, Loperamide and the Combination to Treat Travelers' DiarrheaCompletedNCT00292344Phase 4
- The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic EncephalopathyStatus unknownNCT00281502Phase 2
- Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel SyndromeCompletedNCT00269412Phase 2
- Rifaximin for the Treatment of Irritable Bowel SyndromeCompletedNCT00259155Phase 2
- Rifaximin Versus Placebo in the Prevention of Travelers' DiarrheaCompletedNCT00098384Phase 2